

Hana Biosciences (NASDAQ: HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. We are committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding our pipeline by being the alliance partner of choice, and nurturing a unique company culture.

	Preclinical	Phase I	Phase II	Phase III	NDA	Market
THERAPEUTICS						
Marqibo® (vincristine sulfate liposomes injection)						
Acute Lymphocytic Leukemia (ALL)						
Non-Hodgkin's Lymphoma (NHL)						
Alocrest™ (vinorelbine tartrate liposomes injection)						
Solid Tumors (Breast, NSCLC)						
Sphingosome Encapsulated Topotecan						
Small Cell Lung Cancer (SCLC)						
Talvesta™ (talotrexin) for Injection						
Solid Tumors						
Non-Small Cell Lung Cancer (NSCLC)						
Acute Lymphocytic Leukemia (ALL)						
SUPPORTIVE CARE						
Zensana™ (ondansetron HCl) Oral Spray						
Chemo, Radiation, and Post-Operative Induced Nausea & Vomiting					505 (b)(2)	
Menadione						
EGFR Inhibitor-Associated Skin Rash						

Complete
Ongoing
Planned

Product Pipeline Summary

Therapeutics

- **Marqibo® (vincristine sulfate liposomes injection) is a novel, targeted sphingosomal formulation of the FDA-approved cancer drug vincristine. Sphingosomal encapsulation of vincristine significantly increases drug delivery to the tumor and provides prolonged drug exposure for cell-cycle specific agents.** Based on clinical trials in over 500 patients to date, including Phase II trials in acute lymphocytic leukemia (ALL) and non-Hodgkins lymphoma (NHL), Hana filed a Special Protocol Assessment (SPA) for Marqibo in ALL in December 2006. A Phase II open-label pivotal trial is targeted to begin in the first half of 2007. Marqibo has been granted an Orphan Drug Designation by the FDA in adult ALL.
- **Alocrest™ (vinorelbine tartrate liposomes injection) is our proprietary formulation of vinorelbine, a microtubule inhibitor that is FDA-approved for use as a single agent or in combination with cisplatin for the first-line treatment of unresectable, advanced NSCLC.** Alocrest started a Phase I clinical trial in solid tumors in August 2006.
- **Sphingosome encapsulated topotecan is our proprietary formulation of topotecan, a topoisomerase I inhibitor that is FDA-approved for use in relapsed small-cell lung cancer and in relapsed ovarian cancer.** Sphingosome encapsulated topotecan is in preclinical development and we plan to file an IND and initiate clinical trials in the second half of 2007.
- **Talvesta™ (talotrexin) for Injection is a novel antifolate drug candidate under development for treatment of various types of tumors.** Talotrexin has demonstrated enhanced antitumor activity in a broad spectrum of cancer models by targeting the enzyme DHFR to prevent DNA synthesis in tumor cells and inhibit tumor growth. We currently have the following trials ongoing: a Phase II clinical trial in ALL, a Phase I/II clinical trial in NSCLC and a Phase I clinical trial in solid tumors. Talvesta has been granted an Orphan Drug Designation by the FDA in ALL.

Supportive Care

- **Zensana™ (ondansetron HCl) Oral Spray is a multidose oral spray 5-HT3 antagonist. Zensana™ is the only multidose oral spray product candidate currently in development that delivers full doses of ondansetron to patients receiving emetogenic chemotherapy.** Ondansetron is an FDA-approved active ingredient that is widely used to prevent chemotherapy, radiation, and post-operative associated nausea and vomiting. Many patients requiring antiemetic therapy may experience dysphagia, a discomfort or difficulty swallowing tablets, due to mouth and throat sores, inflammation, or dry mouth. Drug delivery via an oral spray may offer a convenient and attractive alternative to tablets and other forms of ondansetron. Hana filed a New Drug Application (NDA) under section 505(b)(2), a form of registration that relies on data in previously approved NDAs and published literature.
- **Menadione is our preclinical product candidate for the prevention and treatment of skin rash associated with the use of epidermal growth factor receptor (EGFR) inhibitors in the treatment of certain cancers.** We plan to file an IND in the second half of 2007.

2007 Key Milestones

Therapeutics

- **Marqibo® (vincristine sulfate liposomes injection)**
 - ❑ 1H: Initiate Phase II supporting trial in relapsed refractory acute lymphoblastic leukemia (ALL)
 - ❑ 1H: Initiate Phase II Registrational Trial in relapsed refractory acute lymphoblastic leukemia (ALL) under a SPA
 - ❑ 2H: Initiate Phase III Frontline Trial in acute lymphoblastic leukemia (ALL)
- **Alocrest™ (vinorelbine tartrate liposomes injection)**
 - ❑ 2H: Complete Phase I trial in solid tumors
 - ❑ 2H: Initiate Phase II trial in a solid tumor
- **Sphingosine Encapsulated Topotecan**
 - ❑ 2H: Initiate Phase I in solid tumors
- **Talvesta™ (talotrexin) for Injection**
 - ❑ 2H: Complete Q3 Weekly Solid Tumor Phase I trial
 - ❑ 2H: Initiate Phase II non small cell lung cancer (NSCLC) trial
 - ❑ Q4: Complete Phase II acute lymphoblastic leukemia (ALL) trial

Supportive Care

- **Zensana™ (ondansetron HCl) Oral Spray**
 - ❑ 2H: Complete reformulation and requirements for NDA
- **Menadione**
 - ❑ Q4: Complete IND enabling program

Management Team

Mark J. Ahn, PhD, President & Chief Executive Officer; **Greg Berk, MD**, Senior Vice President & Chief Medical Officer; **Gavin Choy, PharmD**, Vice President, Clinical Operations; **John Iparraguirre**, Vice President & Chief Financial Officer; **Alex Tkachenko, PhD**, Vice President, Corporate Development and Strategic Planning; **Fred Vitale**, Vice President & Chief Business Officer.

Scientific Advisory Board

Ken Anderson, MD, Kraft Family Professor of Medicine at Harvard Medical School; **James O. Armitage, MD**, Professor, Internal Medicine at the University of Nebraska Medical Center; **Robert A. Figlin, MD**, Professor of Medicine and Urology, Henry Alvin and Carrie L. Meinhardt Chair in Urologic Oncology at the Jonsson Comprehensive Cancer Center, UCLA School of Medicine; **Hagop M. Kantarjian, MD**, Professor and Chairman, Department of Leukemia at the University of Texas M.D. Anderson Cancer Center; **Thomas Lynch, Jr., MD**, Associate Professor of Medicine at the Harvard School of Medicine and Director Medical Oncology at the Massachusetts General Hospital Thoracic Oncology Center; **Nicholas Vogelzang, MD**, Director, Nevada Cancer Institute and Clinical Professor of Medicine at the University of Nevada School of Medicine.

Board of Directors

Mark J. Ahn, PhD, President & CEO, Hana Biosciences, Inc.; **Arie Beldegrun, MD, FACS**, Chief of Urologic Oncology, UCLA School of Medicine; **Ike Kier, JD**, Principal, Kier Global, LLC; **Lee Rosenberg, MD**, Professor of Molecular Biology, Princeton University; **Michael Weiser, MD, PhD**, Founder & Co-chairman, Actin Biomed, LLC; **Lyn Wiesinger**, formerly Pfizer, Rhone-Poulenc Rorer, Bristol-Myers Squibb and Vicuron Pharmaceuticals.

Company Contact:

Remy Bernarda
Director, Investor Relations
T: (650) 288-2769
Email: investor.relations@hanabiosciences.com

This fact sheet contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Hana's product candidates, the risk that the results of clinical trials may not support Hana's claims, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2006 filed with the Securities and Exchange Commission. Hana assumes no obligation to update these statements, except as required by law.